Triple therapy may improve asthma symptoms, particularly among patients requiring systemic corticosteroids to treat severe exacerbations, a study finds. Adding long-acting muscarinic antagonists ...

Respiratory Drugs Long-acting muscarinic antagonists (LAMA) have been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and are now being considered for patients with ...

Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...

Adding a LAMA to inhaled corticosteroids reduces the risk for asthma exacerbations compared with placebo plus inhaled corticosteroids, according to one review. However, the combination was no better ...

European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with ...

In keeping with the new trend for providing "living guidelines," the Global Initiative for Asthma (GINA) Scientific Committee released their latest update a few months ago. The push toward earlier ...

Please provide your email address to receive an email when new articles are posted on . Doubling the inhaled corticosteroid dose and adding umeclidinium to inhaled ...

Please provide your email address to receive an email when new articles are posted on . Among new initiators of multiple-inhaler triple therapy for asthma, discontinuation was high, although ...

Basel, May 1, 2020 — Novartis today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval ...

Compared with other racial and ethnic groups, a greater proportion of White adults utilized inhaled corticosteroid (ICS), long-acting β-agonist (LABA), and long-acting muscarinic antagonist (LAMA) ...